{"id":"NCT01776424","sponsor":"Bayer","briefTitle":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","officialTitle":"A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02-28","primaryCompletion":"2017-07-21","completion":"2021-06-15","firstPosted":"2013-01-28","resultsPosted":"2018-10-05","lastUpdate":"2022-11-28"},"enrollment":27395,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Prevention & Control"],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"type":"DRUG","name":"Aspirin","otherNames":[]},{"type":"DRUG","name":"Aspirin placebo","otherNames":[]},{"type":"DRUG","name":"Rivaroxaban placebo","otherNames":[]},{"type":"DRUG","name":"Pantoprazole","otherNames":[]},{"type":"DRUG","name":"Pantoprazole placebo","otherNames":[]}],"arms":[{"label":"Rivaroxaban 2.5mg + Aspirin 100mg","type":"EXPERIMENTAL"},{"label":"Rivaroxaban 5mg + Aspirin Placebo","type":"EXPERIMENTAL"},{"label":"Rivaroxaban Placebo + Aspirin 100mg","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objectives of this study are:\n\n* To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD);\n* To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.","primaryOutcome":{"measure":"The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death","timeFrame":"For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.","effectByArm":[{"arm":"Rivaroxaban 2.5mg + Aspirin 100mg","deltaMin":379,"sd":null},{"arm":"Rivaroxaban 5mg + Aspirin Placebo","deltaMin":448,"sd":null},{"arm":"Rivaroxaban Placebo + Aspirin 100mg","deltaMin":496,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.00004"},{"comp":"OG001 vs OG002","p":"0.11490"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":565,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Ecuador","Finland","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Malaysia","Netherlands","Philippines","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Sweden","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["35383832","29540326","28844192","28754388","28844176","29372976","29132877","29186454","29661947","29945212","30058959","29346127","30220379","30417662","30213508","30354448","30654882","30667279","30702997","31054846","31072566","31146821","31152740","31144674","31163978","31248549","31248548","31358978","31504399","31510769","31524941","31537259","30916315","31615291","31807773","31715433","30538057","32178526","32289159","32223318","32436455","32951537","32997098","33538248","33957178","34021038","34132753","34191011","34210409","34463737","31321405","40490702","39439530","39002945","38914270","38602780","38153624","37565307","36646196","36444513","36409491","36001989","35760616","32651298","29132880","29132879"],"seeAlso":["https://clinicaltrials.bayer.com/"]},"adverseEventsSummary":{"seriousAny":{"events":692,"n":9134},"commonTop":["Nasopharyngitis","Diarrhoea","Epistaxis","Contusion","Back pain"]}}